Tokyo, Japan

Taisuke Iwanami

This inventor holds 1 USPTO granted patent and 3 published patent applications and 1 EPO patent. Top assignee: Asahi Kasei Pharma Corporation. Active years: 2011.

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2011

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Taisuke Iwanami: Innovator in Indazole Compounds

Introduction

Taisuke Iwanami is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly through his work on indazole compounds. His innovative research has the potential to impact various therapeutic areas.

Latest Patents

Iwanami holds a patent for indazole compounds, which are represented by specific chemical formulas. These compounds exhibit β3 adrenergic receptor agonist activity, making them useful as therapeutic and prophylactic agents for conditions such as diabetes mellitus, obesity, hyperlipidemia, depression, and urinary incontinence. The patent highlights the versatility of these compounds in addressing multiple health issues.

Career Highlights

Throughout his career, Taisuke Iwanami has worked with prominent companies, including Asahi Kasei Pharma Corporation and Asahi Kasei Fibers Corporation. His experience in these organizations has allowed him to develop and refine his expertise in pharmaceutical innovations.

Collaborations

Iwanami has collaborated with esteemed colleagues, including Seiji Nakano and Kei Yamanishi. These partnerships have contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Taisuke Iwanami's work in the field of indazole compounds showcases his dedication to innovation in pharmaceuticals. His contributions have the potential to improve the treatment of various medical conditions, highlighting the importance of ongoing research and development in this area.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…